Open Access

Topology and biological function of enterovirus non-structural protein 2B as a member of the viroporin family

Veterinary Research201445:87

https://doi.org/10.1186/s13567-014-0087-6

Received: 6 December 2013

Accepted: 8 August 2014

Published: 28 August 2014

Abstract

Viroporins are a group of transmembrane proteins with low molecular weight that are encoded by many animal viruses. Generally, viroporins are composed of 50-120 amino acid residues and possess a minimum of one hydrophobic region that interacts with the lipid bilayer and leads to dispersion. Viroporins are involved in destroying the morphology of host cells and disturbing their biological functions to complete the life cycle of the virus. The 2B proteins encoded by enteroviruses, which belong to the family Picornaviridae, can form transmembrane pores by oligomerization, increase the permeability of plasma membranes, disturb the homeostasis of calcium in cells, induce apoptosis, and cause autophagy; these abilities are shared among viroporins. The present paper introduces the structure and biological characteristics of various 2B proteins encoded by enteroviruses of the family Picornaviridae and may provide a novel idea for developing antiviral drugs.

Table of contents

  1. 1.

    Introduction

     
  2. 2.

    Translation of enterovirus 2B protein

     
  3. 3.

    Transmembrane domain and membrane topology of enterovirus 2B protein

     
  4. 4.
    Effects of the ion channel characteristics of enterovirus non-structural protein 2B on host cells
    1. 4.1

      4.1 Increases the permeability of membrane structure in host cells

       
    2. 4.2

      Disturbs Ca2+ balance in host cells

       
    3. 4.3

      Induces apoptosis of host cells

       
    4. 4.4

      Induces cell autophagy

       
     
  5. 5.

    Strategy of antiviral drug design based on viroporins and other viral proteins with viroporin-like activity

     
  6. 6.

    Conclusion and future perspectives

     
  7. 7.

    List of abbreviations

     
  8. 8.

    Competing interests

     
  9. 9.

    Authors' contributions

     
  10. 10.

    Authors' information

     
  11. 11.

    Acknowledgements

     
  12. 12.

    References

     

1. Introduction

As a consequence of long-term evolution, animal viruses have acquired the ability to damage the normal physiological functions of their host cells after infection to ensure their replication and the completion of their life cycles. One of the damages inflicted is increased permeability of the host cell membrane, a phenomenon induced by the protein products of various viral genes, including viral proteases such as non-structural protein 2B and non-structural protein 3 of encephalitis B virus, glycoproteins, and viroporins [1]-[4].

Viroporins are a family of low-molecular weight hydrophobic transmembrane proteins encoded by animal viruses. Viroporins generally comprise 50-120 amino acid residues and have a minimum of one transmembrane domain. The transmembrane hydrophobic regions can interact with the phospholipid bilayer to induce dispersion, thus increasing membrane permeability and promoting the release of viral particles [2]-[9]. With the increasing comprehensive studies on viroporins, their functions in the life cycle of a virus have gained significant attention. Currently, viroporins are important in promoting virus replication and in disrupting the electrochemical equilibrium in host cells. The oligomerization of monomers in the membrane structure of host cells leads to the formation of hydrophobic pores, which increase the permeability of the host cell membrane and promote the budding of viral particles. Moreover, viroporins affect the cell vesicular transport system and glycoprotein transport process. In addition, other studies have demonstrated that viroporins are involved in destroying the shape of host cells and in disturbing their normal physiological functions to ensure completion of the entire viral life cycle. Virologists are currently focusing on the biological functions of viroporins and their involvement in viral pathogenesis.

A study in 1992 showed that influenza A virus M2 protein exhibits viroporin activity and has important functions in the viral life cycle [10]. Subsequently, proteins encoded by other viruses, such as the non-structural protein 2B of enterovirus, have similar characteristics [7]. In this review, we summarize the virus infection mechanisms by introducing the topology of enterovirus non-structural protein 2B and its biological features as a viroporin to provide new ideas for studying and developing novel antiviral intervention methods and drugs.

Translation of enterovirus 2B protein

The Enterovirus genus belongs to the Picornaviridae family, which includes poliovirus, Coxsackie virus, enteric cytopathogenic human orphan virus, and human enterovirus 71 (EV71). Non-enveloped enterovirus is spherical in shape, with a diameter ranging from 28 nm to 30 nm. Its nucleocapsid is an icosahedron, and the viral capsid consists of 60 copies of capsid proteins arranged into 12 pentamers. The genome of this virus family contains a single-stranded positive-sense RNA with 7500 to 8000 nucleotides and a single open reading frame. RNA encodes a peptide chain with approximately 2200 amino acid residues. This peptide chain is divided factitiously into three regions, P1, P2, and P3, based on the differences in its structure and function. P1 constitutes the capsid protein fraction of the virus, whereas P2 and P3 comprise the non-structural proteins of the virus. P1 is cleaved by the viral protease Lpro into four viral capsid proteins: 1A (VP4), 1B (VP2), 1C (VP3), and 1D (VP1). The four structural proteins envelop the viral RNA into the icosahedral capsid using a highly ordered assembly process. The peptides in P2 and P3 initially generate three non-structured protein precursors: 2BC, 3AB, and 3CD. Finally, these precursors are cleaved into several non-structural proteins by the following proteases (2Apro and 3Cpro): 2A, 2B, 2C, 3A, 3B (VPg), 3C, and 3D proteins (Figure 1) [11]. The 2B protein is one of the products from the polypeptides in the P2 region.
Figure 1

Map of proteins encoded by the RNA of Enterovirus . The Enterovirus-code peptide chain is factitiously divided into three segments: P1, P2, and P3. Peptide P1 is digested into four structural proteins: VP1-4, whereas peptides P2 and P3 are further digested into various non-structural proteins.

Transmembrane domain and membrane topology of enterovirus 2B protein

Various studies have provided profound insights into the viroporin structure. The currently accepted mode of action for viroporin is the polymerization of monomers to form hydrophilic pores and to exert their functions after being embedded into the host cell membrane. Viroporins can be divided into type I and type II based on the presence of one or two transmembrane regions. Moreover, both types can be further divided into subtypes IA, IB, IIA, and IIB based on their transmembrane topology [12]. Figure 2 shows the four types of viroporins. The N terminal of type IA viroporins faces the organelle lumen, and the C terminal faces the cytoplasmic matrix (Figure 2A). By contrast, the C-terminus of type IB viroporins faces the organelle lumen and the N-terminus faces the cytoplasmic matrix (Figure 2B). The C- and N-termini of type IIA viroporins stretch to the organelle lumen (Figure 2C), whereas the C- and N-termini of type IIB viroporins extend to the cytoplasm (Figure 2D).
Figure 2

Sketch map of the transmembrane topology of viroporins. The four types of viroporins based on their transmembrane topologies. (A) and (B) represent type IA and type IB viroporins, respectively. These viroporins possess only one transmembrane domain with inverse orientations. (C) and (D) represent type IIA and type IIB viroporins, respectively. These viroporins possess two transmembrane domains with opposite orientations. Adapted from [12].

Poliovirus 2B protein consists of approximately 100 amino acid residues and has two hydrophobic domains: HR1 (32VTSTITEKLLKNLIKIISSLVIITG55) and HR2 (61TTTVLATLALLGCDASPWQWL81). For these two hydrophobic domains, the HR1 domain crosses the cell membrane via a cationic amphiphatic α-helix, whereas the HR2 domain is a complete hydrophobic transmembrane region [13]. The HR1 and HR2 domains of the protein are located in the endoplasmic reticulum (ER) through an angled annular serial connection by mutual cooperation, such that the C- and N-termini of the polypeptide chain stretch to the ER and Golgi lumen [13]-[15].

The Coxsackie virus-coded 2B protein is also a transmembrane protein with 99 amino acid residues and consists of two hydrophobic domains: HR1 (37SILEKSLKALVKIISALV54) and HR2 (63LITVTATLALIGCTSSPW80) [15],[16]. HR1 forms a cationic amphiphilic α-helix, whereas HR2 forms a completely hydrophobic helix [17].

Mutation analysis reveals that the lack of HR1 or HR2 causes the 2B protein to remain integrated with the host cell membrane; however, translocation across the membrane or oligomerization cannot be completed. The mutant 2B protein without HR1 or HR2 has no biological activity compared with the wild-type 2B protein [13],[15]. These studies have demonstrated that the HR1 and HR2 domains are necessary for the interaction of the 2B protein with the membrane structure of the host cell. Two hydrophobic domains and the stem loop connecting them interact to form a "helix-angle-helix" structure. After the interaction, the protein could successfully embed into the membrane. Finally, normal oligomerization is completed and transmembrane pores with biological function are formed [13].

The poliovirus-coded 2B protein belongs to type IIB, whereas Coxsackie virus-coded 2B protein is a member of type IIA viroporins. This classification is based on the membrane topologies and on the classification criteria mentioned.

On the basis of the mutation of hydrophobic domains of the enterovirus-coded 2B protein, we speculate that the integrality of these hydrophobic structures and the interactions between them are crucial to the biological functions of the 2B protein. These findings may provide a breakthrough for future research and development of antiviral drugs.

Effects of the ion channel activity of enterovirus 2B protein on host cells

After infecting susceptible cells with an animal virus, the structure and function of the host cells significantly change. These changes include increased intracellular vesicle formation, increased membrane permeability, disrupted Ca2+ balance in cells, cell apoptosis, and induced autophagy [5],[13]. Some of these functional and morphological changes can also be observed in cells expressing the enterovirus-coded 2B protein only [9],[13],[18],[19]. The viroporin features of the 2B protein that affect the biological functions of host cells are summarized in the following aspects.

Increases the permeability of the membrane structure in host cells

Biochemical analysis of the enterovirus 2B protein sequence shows its two hydrophobic domains [15]. Self-polymerization reaction in a single lipid membrane in vitro, in vivo yeast and mammalian cell two-hybrid analysis, and fluorescence resonance energy transfer microscopy of live cells confirm that the 2B protein is a transmembrane protein [14],[20]. Moreover, data obtained from the biochemical analysis of the 2B protein are highly consistent with its molecular dynamic data. Previous studies have shown that the C- and N-termini of poliovirus 2B protein are exposed to the ER and Golgi lumen when expressed in cells [13]-[15]; however, the C and N-termini of Coxsackie virus 2B protein are located in the cytoplasm [15],[16]. The 2B protein may assemble into hydrophilic pores with diameters ranging from 5 Å to 7 Å in the form of a tetramer in the lipid bilayer [21]. When mutations are induced in the hydrophilic domain (58RNHDD62) between HR1 and HR2 of Coxsackie virus 2B protein, the protein cannot self-polymerize in the lipid layer in vitro or in the host cell membrane [14],[22].

After being infected with an animal virus, a typical pathological change of the host cells is the significant increase in the permeability of the cellular membrane. The increased permeability starts from the changes in Ca2+ content and the disruption of ionic gradients outside the membrane [18]. When the enterovirus-coded 2B protein is expressed independently in susceptible cells, cell permeability increases, such that non-specific selective ions and solutes with low molecular weights (< 1000 Da) freely flow in or out [12],[13]. The increased membrane permeability in the cells infected with enteroviruses or the cells overexpressing the 2B protein has been demonstrated by the following experiments. The β-galactosidase in Escherichia coli cannot be released and O-nitrophenyl β-D-galactopyranoside (ONPG) cannot pass into E. coli through the complete cell membrane under normal conditions. However, after inducing the expression of the 2B protein in E. coli BL21 (DE3), the addition of ONPG to the bacterial culture suspension changes the color to yellow [23]; its interaction with β-galactosidase forms a yellow product. Second, the impermeable translation inhibitor hygromycin B was used to reveal that the virus-coded 2B protein can increase the permeability of the membrane [24]. Furthermore, non-specific selective ions and solutes with low molecular weights (< 1500 Da) freely pass through the plasma membrane when poliovirus 2B protein is embedded into the liposomes or expressed in BHK-21 cells; moreover, the intrinsic proton gradients at both sides of the membrane are disturbed [9],[13]. Similar to the function of poliovirus 2B protein, membrane permeability increases after the 2B gene in Coxsackie virus B3 was expressed in green monkey kidney cells [25]. Except when proton gradients at both sides are destroyed and when hygromycin B is allowed to freely flow outside, the pH in the Golgi membrane evidently increases with the development of infection [19]. All these studies have proven that the 2B protein increases the permeability of the host cell plasma membrane.

The following two mechanisms are initially hypothesized to be responsible for the increase in cell membrane permeability: (1) after polypeptide chain cleavage, the resulting mature protein covers the membrane surface in a carpet pattern to destroy the bending degree of the phospholipid bilayer, thereby affecting membrane permeability; and (2) after polypeptide chain cleavage, the monomers of the protein are formed. The oligomerization in the membrane structure of host cells and the formation of transmembrane pores subsequently occur to increase membrane permeability [26]. The increased permeability causes damage in the membrane structure of host cells. This process is very important for the virus to complete its life cycle. The increased cell membrane permeability changes the original physiological state of the host cell and facilitates the completion of replication and viral assembly of a virus, as well as the budding of the progeny virus. The enterovirus-coded 2B protein forms transmembrane pores that rely on the two hydrophobic transmembrane domains only. This established phenomenon affects membrane permeability and has very important functions in the viral life cycle.

Disturbs Ca2+ balance in host cells

Another significant effect of enterovirus 2B protein on host cells is the disruption of Ca2+ balance in cells. Ca2+, an important ion in cells, controls the activation of various intracellular enzymes and is involved in their catalytic processes. Ca2+ also has important functions in viral replication and various physiological processes [27]. At normal physiological state, intracellular Ca2+ retains a dynamic balance in the free and bound states. After infecting the cells with poliovirus for 4 h, the Ca2+ content in the cytoplasm increases. The 2B precursor 2BC also exerts similar effect after being expressed in HeLa cells [18]. Some studies have reported that the independent expression of Coxsackie virus 2B protein is sufficient to increase the Ca2+ levels in the cytoplasm significantly [28].

Preliminary studies have shown that the Ca2+ levels in the cytoplasm increase in cells expressing the 2B protein only, but the source of Ca2+ ions is unknown. Moreover, Coxsackie virus infection induces a decrease in the Ca2+ content in the ER and Golgi, as well as a decrease in the mitochondrial uptake of Ca2+[28],[29]. On the basis of these observations, scholars have proposed two possible mechanisms of the 2B protein: (1) induces the extracellular Ca2+ inflow; and (2) disrupts the ER and Golgi membranes to cause outflow of the stored Ca2+ ions into the cytoplasm [30].

Ca2+-ATPase in the ER can transfer Ca2+ from the cytoplasm into the ER to compensate for the lost Ca2+. Using thapsigargin to inhibit the activation of Ca2+-ATPase in the ER reveals that the expressions of poliovirus and Coxsackie virus 2B proteins in host cells promote Ca2+ outflow from the ER [18],[30]. However, the increased Ca2+concentration in the ER is mainly due to the extracellular Ca2+ inflow [18].

Some studies used poliovirus to infect human neuroblastoma IMR5 cells, which grow in a culture medium without Ca2+. As a result, the Ca2+ concentrations in the ER increase [31]. Inhibiting the ryanodine receptor (RyR) and inositol-1,4,5-triphosphate receptor (IP3R), which control the Ca2+ inflow and outflow in the ER, decreases the Ca2+ content in the cytoplasm. These results indicate that the virus affects RyR and IP3R to alter the Ca2+ levels [31]. However, no direct evidence has supported the conclusion that the 2B protein induces changes in the Ca2+ content. More complex mechanisms are possibly involved, and further detailed investigations should be carried out.

Regulates apoptosis in host cells

Apoptosis is a process of cell death caused by various stimuli, including virus infection. This process is achieved via the following two pathways: (1) exogenous pathway, where stimuli activate the death receptors Fas or CD95 on the cell surface; and (2) endogenous pathway, where increased permeability of the mitochondrial membrane and ER stress occurs [32]. In the mitochondrial pathway, the permeability of the mitochondrial membrane increases. Transmembrane potential is disrupted, and proapoptotic molecules are released [27].

An increasing number of studies have shown that the Ca2+ exchange between the ER and mitochondria has a very important function in the apoptotic process in the ER-dependent pathway [27]-[29],[33]. The excessive mitochondrial uptake of Ca2+ has toxic effects on cells; high Ca2+ concentrations can open the mitochondrial permeability transition pores, expand mitochondrial permeability, and rupture the mitochondrial outer membrane. Consequently, cytochrome C and other pro-apoptotic factors are released, eventually leading to apoptosis (Figure 3).
Figure 3

Sketch map of apoptosis and autophagy induced by protein 2B. The 2B protein can embed into the cytomembrane, ER, and mitochondrial membrane to increase cell permeability, disturb intracellular Ca2+ equilibrium, and ultimately induce apoptosis and autophagy of host cells. Adapted from [26] and [34].

Zhou et al. found that the expression of poliovirus and Coxsackie virus 2B proteins can decrease the Ca2+ levels in the ER, Golgi, and mitochondria [27]. De Jong et al. also found a similar effect of Coxsackie virus 2B protein on the efflux of Ca2+ in the Golgi apparatus [19]. This effect possibly has two functions. The first function is the inhibition of the protein transition pathway in cells to promote viral replication and repression of the antiviral immune response of host cells. The decreased Ca2+ content in these organelles inhibits the transport of protein by the vesicles. The vesicles generated from the ER or Golgi also accumulate in the cytoplasm. Viral RNA replication occurs in the vesicles [27]. All viral proteins required for RNA replication and the newly synthesized viral RNA are associated with the surfaces of these virus-induced vesicles. The cells infected with poliovirus have many accumulated virus-induced vesicles. After isolation from infected cells, the replication complex is found in the center of a rosette-like cluster formed by many virus-induced vesicles [35],[36]. The replication complex is attached to the vesicular membranes and is enclosed through the plus strands of the replicative intermediate protrude from the central part of the complex. Finally, progeny 36S RNA is released on the surface of the rosette [36]. In addition, the alphavirus RNA replication complexes on the surfaces of the membranous vesicles have endosomal origin [37]. The formation of the replication complexes requires active viral RNA replication. The membrane structure is essential for initiating RNA synthesis reaction [36]-[38]. The second function is temporary anti-apoptosis. After viral invasion, the apoptotic program immediately starts in the cells. However, at the middle stages of viral infection, apoptosis suddenly stops. Mature apoptosis subsequently recovers at the late stages of viral infection.

Poliovirus and Coxsackie virus can initiate the apoptotic program in HeLa cells after infection through inhibiting intracellular transcription. However, at the start of infection, the apoptosis of host cells suddenly stops with the development of viral replication [29]. After viral replication, the entire apoptotic signal becomes evident [39]. These results demonstrate that apoptosis is partially inhibited or delayed to ensure that viral replication processes are completed after enterovirus infection.

Poly-(ADP-ribose) polymerase, a caspase-3 substrate, is cleaved significantly in the poliovirus 2B protein-expressing cells, and caspase-3 is activated subsequently. The mitochondria in these cells expressing poliovirus 2B protein exhibit punctated entities instead of the typical long shape [5]. These results reveal that poliovirus 2B protein can induce apoptosis. Moreover, the Coxsackie virus 2B protein expressed in HeLa cells inhibits apoptosis caused by cycloheximide and actinomycin D [28]. An evidence also indicate that these phenomena are due to the disruption of Ca2+ balance in cells caused by the 2B protein [29]. Moreover, the 2B protein forms transmembrane pores in the ER and Golgi membrane; thereby, decreasing the Ca2+ content and generating extracellular Ca2+ inflow. In addition, the uptake of Ca2+ by the mitochondrion decreases and the Ca2+ signal transmission between the ER and mitochondrion is disrupted; thus, apoptosis is terminated. At the late stage of viral infection, the permeability or potential energy of the mitochondrial membrane is damaged and thus causes the mitochondria to absorb the excess Ca2+ and release very high amounts of cytochrome C [27]. The mature apoptotic signal in the host cells was observed, and a mass of cytochrome C was detected in the cytoplasm. The infected cells eventually die, and viral particles are enclosed in the apoptotic bodies whose phagocytosis by neighboring cells provide a potential method for viral distribution [40].

Regulates cell autophagy

The infected cells ultimately undergo apoptosis to release viral particles. However, at the start of viral infection, apoptosis does not immediately occur to contend with viral infection but autophagy occurs first. Autophagy is a necessary process to balance the degrading and reusing of the intracellular components in response to nutritional deficiency and other stresses [41],[42]. Some studies have shown that cell autophagy can balance the favorable and unfavorable effects of organism immunity and inflammation to help organisms fight various contagious autoimmune and inflammatory diseases [34]. Other studies have also demonstrated that EV71 infection increases the number of autophagosomes in cells and inhibits the cell apoptotic pathway [43]. A mass of viruses are replicated during this period, which is similar to a phenomenon observed when Coxsackie virus B3 is used to infect cells [44].

Many viroporins, such as influenza A virus-encoded M2 protein, rotavirus-encoded non-structure protein 1, non-structural protein 4 (NSP4), and yellow fever virus-encoded non-structural protein 4A, can induce cell autophagy and inhibit cell apoptosis to promote viral multiplication [45]-[48]. Studies on NSP4 of rotavirus have demonstrated that the protein induces the release of Ca2+ from the ER to the cytoplasm during viral replication. Ca2+/calmodulin-dependent protein kinases-β kinases and 5′ adenosine monophosphate-related protein-dependent signal pathways are activated resulting in cell autophagy. However, the maturation of autophagosomes is inhibited. Autophagic vesicle membranes are used to transfer viral proteins from the ER to the corresponding replication and assembly sites [48]. The maturation of autophagosomes is inhibited during enterovirus infection, and intracellular vesicles become abundant during enterovirus 2B protein process. The vesicles secreted from the Golgi apparatus function as viral RNA replication sites [27]. Other scholars have indicated that protein secretion through the Golgi apparatus is inhibited to a certain extent [33]. Our research also found that autophagy is induced after the cells were transfected with the plasmid-encoded 2B protein of foot and mouth disease virus FMDV (unpublished data).

5. Strategy for antiviral drug design based on viroporins and other viral proteins with viroporin-like activity

Over the recent years, studies have focused on the structure and functions of various viral viroporins; the studies and design of antiviral drugs based on viroporins and other viral proteins with viroporin-like activity have made an important breakthrough. Currently, the development of these antiviral drugs in this pathway mainly focuses on three aspects. The first aspect is the design of fusion inhibitors. The designed drugs can inhibit the fusion of protein and cell membrane. Bosch et al. indicated that the coronavirus-coded S protein is a transmembrane protein that pertained to type I viroporin. The HR1 region of the S protein can inhibit the fusion between virus and cell membranes after mutation. The second aspect is the design of the ion channel inhibitors. These inhibitors can prevent viroporin activity to form an ion channel. The inhibitory effect of amantadine on influenza A virus M2 protein illustrates a good example. The third aspect is the design of membrane protein antibodies. The antibody that specifically affects membrane proteins should be determined to inhibit viral invasion by removing the protein or blocking membrane fusion. Studies on human immunodeficiency virus-encoded envelope protein, known as gp160, confirmed the efficiency of this method [49],[50].

Four inhibitors inhibit the viroporin activity based on these strategies. First, amantadine, a widely studied compound, can inhibit the uncoating of influenza A viruses by interacting with the M2 protein [51]. Amantadine is located inside the virus M2 channel; amantadine localizes to the histidine gate and facilitates the orientation of His37 imidazole rings to lie in the close conformation. In addition, amantadine functions as a blocker when interacting with three pore-lining residues: Leu26, Ala30, and Ser31 [52],[53]. Amantadine also inhibits the ion channel activity of the p7 protein of Hepatitis C Virus (HCV) [54] and the C-terminal subunit of the p13 protein (p13-C) of the GB virus B (GBV-B), which is closely related to HCV [55]. Second, the long-alkyl-chain iminosugar derivatives inhibit the HCV p7 protein to form an ion channel [56]. The results show that N-butyl-glucose analogue deoxynojirimycin and N-nonyl-galactose analogue deoxygalactonojirimycin, which contain the short-alkyl-chain, do not affect the p7 channel activity. However, the long-alkyl-chain derivatives, including N-nonyl-glucose analogue deoxynojirimycin, N-nonyl-galactose analogue deoxygalactonojirimycin, and N-7-oxanonyl-6-deoxy-DGJ, dose-dependently inhibit the p7 channel signals with 105, 140, and 180 μM, respectively [54],[56],[57]. Third, amiloride, a drug used in the treatment of hypertension and congestive heart failure, blocks the ion channel activity and enhances the virus-like particle budding caused by human immunodeficiency virus 1 (HIV-1) Vpu [58]. Moreover, hexamethylene amiloride blocks the cation-selective ion channels formed by the p7 protein of HCV [59]. Finally, a novel small molecule, BIT225 (N-[5-(1-methyl-1H-pyrazol-4-yl)-napthalene-2-carbonyl]-guanidine), has been identified as a novel inhibitor of the HCV p7 ion channel [60]. Compared with the effect of BIT225 on HIV-1 release and the Vpu lacked HIV-2 from human macrophages, scholars have found that BIT225 blocks the Vpu ion channel activity and also exhibits anti-HIV-1 activity [61].

The study on the 2B protein coded by virus from Picornaviridae family is relatively delayed. Moreover, the hydrophobic property and diversification of the membrane topology of the 2B protein present many problems. However, cryo-electron microscopy, Fourier-transform infrared spectroscopy, molecular dynamical analogs, and other new technologies have been developed for antiviral drug research; thus, current studies on antiviral drugs based on the 2B protein mechanism considerably progress [62]. Some studies have reported that short-hairpin RNA can affect the 2B gene of Coxsackie virus B3 and inhibit viral replication [63]. Other studies have also demonstrated that BHK cells expressing poliovirus 2B protein can increase the permeability of neighboring normal cells by establishing a "connection" between the cells [64]. All these findings may provide novel methods for studying antiviral drugs based on the 2B protein.

6. Conclusion and future perspectives

Previous studies demonstrated that enterovirus 2B protein has a role in pore formation, and preliminarily analyses on its effects on the viral life cycle were conducted. However, the detailed functional mechanism of the 2B protein requires further study. In particular, elucidating the relationship of viroporin function with the signaling pathway in cells and with regulatory proteins may provide novel information and basis for antiviral treatment by selectively inhibiting specific pathways.

With more studies on the mechanism of enterovirus 2B protein accompanied with the emerging technologies and rapid development in multidisciplinary studies, a quantum progress in the research and development of novel antiviral drugs that target the 2B gene or protein would be expected in the near future.

9. Authors' contributions

DA and HCG conceived the idea, compiled the information, and drafted the paper; SQS critically reviewed and revised the paper. All of the authors agreed to the final version of the manuscript.

Authors' information

Dr Huichen Guo is an associate professor in Lanzhou veterinary research institute, CAAS, China. She has focused on the pathogenesis of animal virus including Classic swine fever virus (CSFV), Foot-and-mouth disease virus (FMDV) and porcine circovirus (PCV2) after doctor graduation. At present, she is studying on viroporin of CSFV and FMDV and apoptosis induced by PCV2 ORF3.

7. Abbreviations

NS2B-NS3: 

Non-structural protein 2B and non-structural protein 3

ECHO-virus: 

Enteric cytopathogenic human orphan virus

EV71: 

Enterovirus 71

NSP1: 

Non-structure protein 1

NSP4: 

Non-structural protein 4

NS4A: 

Non-structural protein 4A

ER: 

Endoplasmic reticulum

IAV: 

Influenza A viruses

HCV: 

Hepatitis C virus

p13-C: 

C-terminal subunit of the p13 protein

GBV-B: 

GB virus B

N B-DNJ N

-butyl-glucose analogue deoxynojirimycin

N N-DGJ N

-nonyl-galactose analogue deoxygalactonojirimycin

N N-DNJ N

-nonyl-glucose analogue deoxynojirimycin

N B-DGJ N

-nonyl-galactose analogue deoxygalactonojirimycin

HIV-1: 

Human immunodeficiency virus 1

HIV-2: 

Human immunodeficiency virus 2

BIT225: 

N-[5-(1-methyl-1H-pyrazol-4-yl)-napthalene-2-carbonyl]-guanidine

Declarations

11. Acknowledgements

This research was supported by grants from the National Science and Technology Support Program (2013BAD12B00), International Science & Technology Cooperation Program of China (2014DFA31890), Gansu Provincial Sci. & Tech. Department (No. 1102NKDA033; No.1102NKDA034; No.1104WCGA185) and National Natural Science Foundation of China (No.31100688; No. 31101838). We are grateful to Dr DX Liu for critically reading and revising the manuscript.

Authors’ Affiliations

(1)
State Key Laboratory of Veterinary Etiological Biology and OIE/National Foot and Mouth Disease Reference Laboratory, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences
(2)
College of Veterinary Medicine, Sichuan Agricultural University

References

  1. Chang YS, Liao CL, Tsao CH, Chen MC, Liu CI, Chen LK, Lin YL: Membrane permeabilization by small hydrophobic nonstructural proteins of Japanese encephalitis virus. J Virol. 1999, 73: 6257-6264.PubMed CentralPubMedGoogle Scholar
  2. Blanco R, Carrasco L, Ventoso I: Cell killing by HIV-1 protease. J Biol Chem. 2003, 278: 1086-1093. 10.1074/jbc.M205636200.View ArticlePubMedGoogle Scholar
  3. Weichert WS, Parker JS, Wahid AT, Chang SF, Meier E, Parrish CR: Assaying for structural variation in the parvovirus capsid and its role in infection. Virology. 1998, 250: 106-117. 10.1006/viro.1998.9352.View ArticlePubMedGoogle Scholar
  4. Gonzalez ME, Carrasco L: Viroporins. FEBS Lett. 2003, 552: 28-34. 10.1016/S0014-5793(03)00780-4.View ArticlePubMedGoogle Scholar
  5. Madan V, Castello A, Carrasco L: Viroporins from RNA viruses induce caspase-dependent apoptosis. Cell Microbiol. 2008, 10: 437-451.PubMedGoogle Scholar
  6. Ichinohe T, Pang IK, Iwasaki A: Influenza virus activates inflammasomes via its intracellular M2 ion channel. Nat Immunol. 2010, 11: 404-410. 10.1038/ni.1861.PubMed CentralView ArticlePubMedGoogle Scholar
  7. Wang K, Xie S, Sun B: Viral proteins function as ion channels. Biochim Biophys Acta. 1808, 2011: 510-515.Google Scholar
  8. Carrasco L, Smith AE: Sodium ions and the shut-off of host cell protein synthesis by picornaviruses. Nature. 1976, 264: 807-809. 10.1038/264807a0.View ArticlePubMedGoogle Scholar
  9. Madan V, Sanchez-Martinez S, Vedovato N, Rispoli G, Carrasco L, Nieva JL: Plasma membrane-porating domain in poliovirus 2B protein. A short peptide mimics viroporin activity. J Mol Biol. 2007, 374: 951-964. 10.1016/j.jmb.2007.09.058.View ArticlePubMedGoogle Scholar
  10. Wang J, Qiu JX, Soto C, DeGrado WF: Structural and dynamic mechanisms for the function and inhibition of the M2 proton channel from influenza A virus. Curr Opin Struct Biol. 2011, 21: 68-80. 10.1016/j.sbi.2010.12.002.PubMed CentralView ArticlePubMedGoogle Scholar
  11. Lin JY, Chen TC, Weng KF, Chang SC, Chen LL, Shih SR: Viral and host proteins involved in picornavirus life cycle. J Biomed Sci. 2009, 16: 103-10.1186/1423-0127-16-103.PubMed CentralView ArticlePubMedGoogle Scholar
  12. Nieva JL, Madan V, Carrasco L: Viroporins: structure and biological functions. Nat Rev Microbiol. 2012, 10: 563-574. 10.1038/nrmicro2820.View ArticlePubMedGoogle Scholar
  13. Nieva JL, Agirre A, Nir S, Carrasco L: Mechanisms of membrane permeabilization by picornavirus 2B viroporin. FEBS Lett. 2003, 552: 68-73. 10.1016/S0014-5793(03)00852-4.View ArticlePubMedGoogle Scholar
  14. Agirre A, Barco A, Carrasco L, Nieva JL: Viroporin-mediated membrane permeabilization. Pore formation by nonstructural poliovirus 2B protein. J Biol Chem. 2002, 277: 40434-40441. 10.1074/jbc.M205393200.View ArticlePubMedGoogle Scholar
  15. de Jong AS, Wessels E, Dijkman HBPM, Galama JMD, Melchers WJG, Willems PHGM, van Kuppeveld FJM: Determinants for membrane association and permeabilization of the coxsackievirus 2B protein and the identification of the Golgi complex as the target organelle. J Biol Chem. 2003, 278: 1012-1021. 10.1074/jbc.M207745200.View ArticlePubMedGoogle Scholar
  16. van Kuppeveld FJM, Galama JMD, Zoll J, van den Hurk PJJC, Melchers WJG: Coxsackie B3 virus protein 2B contains a cationic amphipathic helix that is required for viral RNA replication. J Virol. 1996, 70: 3876-3886.PubMed CentralPubMedGoogle Scholar
  17. de Jong AS, Melchers WJ, Glaudemans DH, Willems PH, van Kuppeveld FJ: Mutational analysis of different regions in the coxsackievirus 2B protein: requirements for homo-multimerization, membrane permeabilization, subcellular localization, and virus replication. J Biol Chem. 2004, 279: 19924-19935. 10.1074/jbc.M314094200.View ArticlePubMedGoogle Scholar
  18. Aldabe R, Irurzun A, Carrasco L: Poliovirus protein 2BC increases cytosolic free calcium concentrations. J Virol. 1997, 71: 6214-6217.PubMed CentralPubMedGoogle Scholar
  19. De Jong AS, Visch HJ, De Mattia F, van Dommelen MM, Swarts HG, Luyten T, Callewaert G, Melchers WJ, Willems PH, van Kuppeveld FJ: The coxsackievirus 2B protein increases efflux of ions from the endoplasmic reticulum and Golgi, thereby inhibiting protein trafficking through the Golgi. J Biol Chem. 2006, 281: 14144-14150. 10.1074/jbc.M511766200.View ArticlePubMedGoogle Scholar
  20. van Kuppeveld FJ, Melchers WJ, Willems PH, Gadella TW: Homomultimerization of the coxsackievirus 2B protein in living cells visualized by fluorescence resonance energy transfer microscopy. J Virol. 2002, 76: 9446-9456. 10.1128/JVI.76.18.9446-9456.2002.PubMed CentralView ArticlePubMedGoogle Scholar
  21. Lama J, Carrasco L: Expression of poliovirus nonstructural proteins in Escherichia coli cells. Modification of membrane permeability induced by 2B and 3A. J Biol Chem. 1992, 267: 15932-15937.PubMedGoogle Scholar
  22. de Jong AS, Schrama IW, Willems PH, Galama JM, Melchers WJ, van Kuppeveld FJ: Multimerization reactions of coxsackievirus proteins 2B, 2C and 2BC: a mammalian two-hybrid analysis. J Gen Virol. 2002, 83: 783-793.View ArticlePubMedGoogle Scholar
  23. Patargias G, Barke T, Watts A, Fischer WB: Model generation of viral channel forming 2B protein bundles from polio and coxsackie viruses. Mol Membr Biol. 2009, 26: 309-320. 10.1080/09687680903164101.View ArticlePubMedGoogle Scholar
  24. FJ V k, Melchers WJ, Kirkegaard K, Doedens JR: Structure-function analysis of coxsackie B3 virus protein 2B. Virology. 1997, 227: 111-118. 10.1006/viro.1996.8320.View ArticleGoogle Scholar
  25. Paloheimo O, Ihalainen TO, Tauriainen S, Valilehto O, Kirjavainen S, Niskanen EA, Laakkonen JP, Hyoty H, Vihinen-Ranta M: Coxsackievirus B3-induced cellular protrusions: structural characteristics and functional competence. J Virol. 2011, 85: 6714-6724. 10.1128/JVI.00247-10.PubMed CentralView ArticlePubMedGoogle Scholar
  26. Shai Y: Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim Biophys Acta. 1999, 1462: 55-70. 10.1016/S0005-2736(99)00200-X.View ArticlePubMedGoogle Scholar
  27. Zhou YB, Frey TK, Yang JJ: Viral calciomics: interplays between Ca2+ and virus. Cell Calcium. 2009, 46: 1-17. 10.1016/j.ceca.2009.05.005.PubMed CentralView ArticlePubMedGoogle Scholar
  28. Campanella M, de Jong AS, Lanke KW, Melchers WJ, Willems PH, Pinton P, Rizzuto R, van Kuppeveld FJ: The coxsackievirus 2B protein suppresses apoptotic host cell responses by manipulating intracellular Ca2+ homeostasis. J Biol Chem. 2004, 279: 18440-18450. 10.1074/jbc.M309494200.View ArticlePubMedGoogle Scholar
  29. van Kuppeveld FJ, de Jong AS, Melchers WJ, Willems PH: Enterovirus protein 2B po(u)res out the calcium: a viral strategy to survive?. Trends Microbiol. 2005, 13: 41-44. 10.1016/j.tim.2004.12.005.View ArticlePubMedGoogle Scholar
  30. van Kuppeveld FJ, Hoenderop JG, Smeets RL, Willems PH, Dijkman HB, Galama JM, Melchers WJ: Coxsackievirus protein 2B modifies endoplasmic reticulum membrane and plasma membrane permeability and facilitates virus release. EMBO J. 1997, 16: 3519-3532. 10.1093/emboj/16.12.3519.PubMed CentralView ArticlePubMedGoogle Scholar
  31. Brisac C, Teoule F, Autret A, Pelletier I, Colbere-Garapin F, Brenner C, Lemaire C, Blondel B: Calcium flux between the endoplasmic reticulum and mitochondrion contributes to poliovirus-induced apoptosis. J Virol. 2010, 84: 12226-12235. 10.1128/JVI.00994-10.PubMed CentralView ArticlePubMedGoogle Scholar
  32. Wang G, Wang X, Yu H, Wei S, Williams N, Holmes DL, Halfmann R, Naidoo J, Wang L, Li L, Chen S, Harran P, Lei X, Wang X: Small-molecule activation of the TRAIL receptor DR5 in human cancer cells. Nat Chem Biol. 2013, 9: 84-89. 10.1038/nchembio.1153.View ArticlePubMedGoogle Scholar
  33. Agirre A, Lorizate M, Nir S, Nieva JL: Poliovirus 2b insertion into lipid monolayers and pore formation in vesicles modulated by anionic phospholipids. Biochim Biophys Acta. 2008, 1778: 2621-2626. 10.1016/j.bbamem.2008.06.013.View ArticlePubMedGoogle Scholar
  34. Levine B, Mizushima N, Virgin HW: Autophagy in immunity and inflammation. Nature. 2011, 469: 323-335. 10.1038/nature09782.PubMed CentralView ArticlePubMedGoogle Scholar
  35. Bienz K, Egger D, Pfister T, Troxler M: Structural and functional characterization of the poliovirus replication complex. J Virol. 1992, 66: 2740-2747.PubMed CentralPubMedGoogle Scholar
  36. Bienz K, Egger D, Pfister T: Characteristics of the poliovirus replication complex. Arch Virol Suppl. 1994, 9: 147-157.PubMedGoogle Scholar
  37. Schlegel A, Giddings TH, Ladinsky MS, Kirkegaard K: Cellular origin and ultrastructure of membranes induced during poliovirus infection. J Virol. 1996, 70: 6576-6588.PubMed CentralPubMedGoogle Scholar
  38. Egger D, Teterina N, Ehrenfeld E, Bienz K: Formation of the poliovirus replication complex requires coupled viral translation, vesicle production, and viral RNA synthesis. J Virol. 2000, 74: 6570-6580. 10.1128/JVI.74.14.6570-6580.2000.PubMed CentralView ArticlePubMedGoogle Scholar
  39. Carthy CM, Yanagawa B, Luo H, Granville DJ, Yang D, Cheung P, Cheung C, Esfandiarei M, Rudin CM, Thompson CB, Hunt DW, McManus BM: Bcl-2 and Bcl-xL overexpression inhibits cytochrome c release, activation of multiple caspases, and virus release following coxsackievirus B3 infection. Virology. 2003, 313: 147-157. 10.1016/S0042-6822(03)00242-3.View ArticlePubMedGoogle Scholar
  40. Mi J, Li ZY, Ni S, Steinwaerder D, Lieber A: Induced apoptosis supports spread of adenovirus vectors in tumors. Hum Gene Ther. 2001, 12: 1343-1352. 10.1089/104303401750270995.View ArticlePubMedGoogle Scholar
  41. Dreux M, Chisari FV: Viruses and the autophagy machinery. Cell Cycle. 2010, 9: 1295-1307. 10.4161/cc.9.7.11109.View ArticlePubMedGoogle Scholar
  42. Taylor MP, Burgon TB, Kirkegaard K, Jackson WT: Role of microtubules in extracellular release of poliovirus. J Virol. 2009, 83: 6599-6609. 10.1128/JVI.01819-08.PubMed CentralView ArticlePubMedGoogle Scholar
  43. Huang SC, Chang CL, Wang PS, Tsai Y, Liu HS: Enterovirus 71-induced autophagy detected in vitro and in vivo promotes viral replication. J Med Virol. 2009, 81: 1241-1252. 10.1002/jmv.21502.View ArticlePubMedGoogle Scholar
  44. Wong J, Zhang J, Si X, Gao G, Mao I, McManus BM, Luo H: Autophagosome supports coxsackievirus B3 replication in host cells. J Virol. 2008, 82: 9143-9153. 10.1128/JVI.00641-08.PubMed CentralView ArticlePubMedGoogle Scholar
  45. Gannage M, Dormann D, Albrecht R, Dengjel J, Torossi T, Ramer PC, Lee M, Strowig T, Arrey F, Conenello G, Pypaert M, Andersen J, García-Sastre A, Münz C: Matrix protein 2 of influenza A virus blocks autophagosome fusion with lysosomes. Cell Host Microbe. 2009, 6: 367-380. 10.1016/j.chom.2009.09.005.PubMed CentralView ArticlePubMedGoogle Scholar
  46. Bagchi P, Dutta D, Chattopadhyay S, Mukherjee A, Halder UC, Sarkar S, Kobayashi N, Komoto S, Taniguchi K, Chawla-Sarkar M: Rotavirus nonstructural protein 1 suppresses virus-induced cellular apoptosis to facilitate viral growth by activating the cell survival pathways during early stages of infection. J Virol. 2010, 84: 6834-6845. 10.1128/JVI.00225-10.PubMed CentralView ArticlePubMedGoogle Scholar
  47. McLean JE, Wudzinska A, Datan E, Quaglino D, Zakeri Z: Flavivirus NS4A-induced autophagy protects cells against death and enhances virus replication. J Biol Chem. 2011, 286: 22147-22159. 10.1074/jbc.M110.192500.PubMed CentralView ArticlePubMedGoogle Scholar
  48. Crawford SE, Hyser JM, Utama B, Estes MK: Autophagy hijacked through viroporin-activated calcium/calmodulin-dependent kinase kinase-beta signaling is required for rotavirus replication. Proc Natl Acad Sci U S A. 2012, 109: E3405-E3413. 10.1073/pnas.1216539109.PubMed CentralView ArticlePubMedGoogle Scholar
  49. Jinhua Y, Rong Y: Advances in the viral transmembrane proteins: structure, function and antiviral drug design. J Microbes Infect. 2009, 4: 231-240.Google Scholar
  50. Bosch BJ, Rossen JWA, Bartelink W, Zuurveen SJ, de Haan CAM, Duquerroy S, Boucher CAB, Rottier PJM: Coronavirus escape from heptad repeat 2 (HR2)-derived peptide entry inhibition as a result of mutations in the HR1 domain of the spike fusion protein. J Virol. 2008, 82: 2580-2585. 10.1128/JVI.02287-07.PubMed CentralView ArticlePubMedGoogle Scholar
  51. Steinmann E, Pietschmann T: Hepatitis C virus p7-a viroporin crucial for virus assembly and an emerging target for antiviral therapy. Viruses. 2010, 2: 2078-2095. 10.3390/v2092078.PubMed CentralView ArticlePubMedGoogle Scholar
  52. Intharathep P, Laohpongspaisan C, Rungrotmongkol T, Loisruangsin A, Malaisree M, Decha P, Aruksakunwong O, Chuenpennit K, Kaiyawet N, Sompornpisut P, Pianwanit S, Hannongbua S: How amantadine and rimantadine inhibit proton transport in the M2 protein channel. J Mol Graph Model. 2008, 27: 342-348. 10.1016/j.jmgm.2008.06.002.View ArticlePubMedGoogle Scholar
  53. Pinto LH, Lamb RA: Controlling influenza virus replication by inhibiting its proton channel. Mol Biosyst. 2007, 3: 18-23. 10.1039/b611613m.View ArticlePubMedGoogle Scholar
  54. Steinmann E, Whitfield T, Kallis S, Dwek RA, Zitzmann N, Pietschmann T, Bartenschlager R: Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Hepatology. 2007, 46: 330-338. 10.1002/hep.21686.View ArticlePubMedGoogle Scholar
  55. Premkumar A, Dong X, Haqshenas G, Gage PW, Gowans EJ: Amantadine inhibits the function of an ion channel encoded by GB virus B, but fails to inhibit virus replication. Antivir Ther. 2006, 11: 289-295.PubMedGoogle Scholar
  56. Pavlovic D, Neville DC, Argaud O, Blumberg B, Dwek RA, Fischer WB, Zitzmann N: The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proc Natl Acad Sci U S A. 2003, 100: 6104-6108. 10.1073/pnas.1031527100.PubMed CentralView ArticlePubMedGoogle Scholar
  57. Meredith LW, Zitzmann N, McKeating JA: Differential effect of p7 inhibitors on hepatitis C virus cell-to-cell transmission. Antiviral Res. 2013, 100: 636-639. 10.1016/j.antiviral.2013.10.006.PubMed CentralView ArticlePubMedGoogle Scholar
  58. Ewart GD, Mills K, Cox GB, Gage PW: Amiloride derivatives block ion channel activity and enhancement of virus-like particle budding caused by HIV-1 protein Vpu. Eur Biophys J. 2002, 31: 26-35. 10.1007/s002490100177.View ArticlePubMedGoogle Scholar
  59. Premkumar A, Wilson L, Ewart GD, Gage PW: Cation-selective ion channels formed by p7 of hepatitis C virus are blocked by hexamethylene amiloride. FEBS Lett. 2004, 557: 99-103. 10.1016/S0014-5793(03)01453-4.View ArticlePubMedGoogle Scholar
  60. Luscombe CA, Huang Z, Murray MG, Miller M, Wilkinson J, Ewart GD: A novel Hepatitis C virus p7 ion channel inhibitor, BIT225, inhibits bovine viral diarrhea virus in vitro and shows synergism with recombinant interferon-alpha-2b and nucleoside analogues. Antiviral Res. 2010, 86: 144-153. 10.1016/j.antiviral.2010.02.312.View ArticlePubMedGoogle Scholar
  61. Khoury G, Ewart G, Luscombe C, Miller M, Wilkinson J: Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages. Antimicrob Agents Chemother. 2010, 54: 835-845. 10.1128/AAC.01308-09.PubMed CentralView ArticlePubMedGoogle Scholar
  62. Liang X, Li ZY: Ion channels as antivirus targets. Virol Sin. 2010, 25: 267-280. 10.1007/s12250-010-3136-y.View ArticlePubMedGoogle Scholar
  63. Yao H, Zhang Y, He F, Wang C, Xiao Z, Zou J, Wang F, Liu Z: Short hairpin RNA targeting 2B gene of coxsackievirus B3 exhibits potential antiviral effects both in vitro and in vivo. BMC Infect Dis. 2012, 12: 177-10.1186/1471-2334-12-177.PubMed CentralView ArticlePubMedGoogle Scholar
  64. Madan V, Redondo N, Carrasco L: Cell permeabilization by poliovirus 2B viroporin triggers bystander permeabilization in neighbouring cells through a mechanism involving gap junctions. Cell Microbiol. 2010, 12: 1144-1157. 10.1111/j.1462-5822.2010.01460.x.View ArticlePubMedGoogle Scholar

Copyright

© Ao et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.